BR112012017051A2 - método para diminuir a imunogenicidade - Google Patents

método para diminuir a imunogenicidade

Info

Publication number
BR112012017051A2
BR112012017051A2 BR112012017051A BR112012017051A BR112012017051A2 BR 112012017051 A2 BR112012017051 A2 BR 112012017051A2 BR 112012017051 A BR112012017051 A BR 112012017051A BR 112012017051 A BR112012017051 A BR 112012017051A BR 112012017051 A2 BR112012017051 A2 BR 112012017051A2
Authority
BR
Brazil
Prior art keywords
decrease immunogenicity
immunogenicity
decreasing
decrease
relates
Prior art date
Application number
BR112012017051A
Other languages
English (en)
Inventor
Urech David
Borras Leonardo
Gunde Tea
Original Assignee
Esbatech Alcon Biomed Res Unit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esbatech Alcon Biomed Res Unit filed Critical Esbatech Alcon Biomed Res Unit
Publication of BR112012017051A2 publication Critical patent/BR112012017051A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

patente de invenção: "método para diminuir a imunogenicidade". a presente invenção refere-se a um método para diminuir a imunogenicidade de domínios variáveis de anticorpos.
BR112012017051A 2009-12-23 2010-12-21 método para diminuir a imunogenicidade BR112012017051A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28944609P 2009-12-23 2009-12-23
PCT/CH2010/000326 WO2011075861A1 (en) 2009-12-23 2010-12-21 Method for decreasing immunogenicity

Publications (1)

Publication Number Publication Date
BR112012017051A2 true BR112012017051A2 (pt) 2017-12-05

Family

ID=43733894

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012017051A BR112012017051A2 (pt) 2009-12-23 2010-12-21 método para diminuir a imunogenicidade

Country Status (16)

Country Link
US (4) US8796425B2 (pt)
EP (3) EP4219545A1 (pt)
JP (6) JP5914353B2 (pt)
KR (3) KR101721187B1 (pt)
CN (2) CN109293768A (pt)
AR (1) AR079700A1 (pt)
AU (1) AU2010335950B2 (pt)
BR (1) BR112012017051A2 (pt)
CA (1) CA2777527C (pt)
CL (1) CL2012001696A1 (pt)
MX (2) MX352871B (pt)
RU (1) RU2585534C2 (pt)
TW (3) TW201925228A (pt)
UY (2) UY33154A (pt)
WO (1) WO2011075861A1 (pt)
ZA (4) ZA201202299B (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009155723A2 (en) * 2008-06-25 2009-12-30 Esbatech, An Alcon Biomedical Research Unit Llc STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFα
CN102143976B (zh) * 2008-06-25 2015-11-25 艾斯巴技术-诺华有限责任公司 抑制vegf的稳定和可溶的抗体
AU2009264567B2 (en) * 2008-06-25 2014-06-12 Novartis Ag Humanization of rabbit antibodies using a universal antibody framework
US8796425B2 (en) * 2009-12-23 2014-08-05 Esbatech, An Alcon Biomedical Research Unit Llc Method for decreasing immunogenicity
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
UY33679A (es) 2010-10-22 2012-03-30 Esbatech Anticuerpos estables y solubles
BR112013032145B1 (pt) * 2011-06-23 2022-09-20 Ablynx N.V Técnicas para prever, detectar e reduzir interferência de proteína não especifica em ensaios envolvendo domínios variáveis únicos de imunoglobulina
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
DK3143403T3 (da) 2014-05-16 2022-01-17 Ablynx Nv Fremgangsmåder til påvisning og/eller måling af anti-lægemiddelantistoffer, især behandlingsinducerede anti-lægemiddelantistoffer
ES2815572T3 (es) * 2014-05-16 2021-03-30 Ablynx Nv Dominios variables de inmunoglobulina
SG11201803416VA (en) * 2015-10-30 2018-05-30 Ablynx Nv Polypeptides against il-23
ES2821099T3 (es) 2015-12-04 2021-04-23 Boehringer Ingelheim Int Gmbh & Co Kg Polipéptidos biparatópicos antagonistas de la señalización WNT en células tumorales
AR108975A1 (es) 2016-07-06 2018-10-17 Celgene Corp Anticuerpos con baja inmunogenicidad y sus usos
KR20200011933A (ko) 2017-05-31 2020-02-04 베링거 인겔하임 인터내셔날 게엠베하 종양 세포에서 wnt 신호 전달을 길항하는 폴리펩티드
EP3569618A1 (en) 2018-05-19 2019-11-20 Boehringer Ingelheim International GmbH Antagonizing cd73 antibody
TW202016151A (zh) 2018-06-09 2020-05-01 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
FR3088640A1 (fr) 2018-10-14 2020-05-22 Smart Diagnostix Pharma Nouveau polypeptide se liant specifiquement a la proteine p16
TW202128756A (zh) 2019-10-02 2021-08-01 德商百靈佳殷格翰國際股份有限公司 用於癌症治療之多重專一性結合蛋白
WO2022136693A1 (en) 2020-12-23 2022-06-30 Numab Therapeutics AG Antibody variable domains and antibodies having decreased immunogenicity
EP4183800A1 (en) 2021-11-19 2023-05-24 Medizinische Hochschule Hannover Novel sars-cov-2 neutralizing antibodies
WO2023110190A1 (en) 2021-12-13 2023-06-22 Heraeus Medical Gmbh Tests and methods for detecting bacterial infection
EP4273162A1 (en) * 2022-05-06 2023-11-08 Numab Therapeutics AG Antibody variable domains and antibodies having decreased immunogenicity
WO2023214047A1 (en) * 2022-05-06 2023-11-09 Numab Therapeutics AG Antibody variable domains and antibodies having decreased immunogenicity
WO2024038095A1 (en) 2022-08-16 2024-02-22 Iome Bio NOVEL ANTI-RGMb ANTIBODIES
EP4357778A1 (en) 2022-10-20 2024-04-24 Heraeus Medical GmbH Treatment of microbial infections diagnosed using the biomarker d-lactate

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2131621A1 (en) 1992-03-18 1993-09-30 Thomas R. Sykes Selective alteration of antibody immunogenicity
WO1998002462A1 (en) 1996-07-16 1998-01-22 Morphosys Gesellschaft Für Proteinoptimierung Mbh Immunoglobulin superfamily domains and fragments with increased solubility
US7132511B2 (en) * 2001-02-19 2006-11-07 Merck Patent Gmbh Modified anti-EGFR antibodies with reduced immunogenicity
US7666414B2 (en) * 2001-06-01 2010-02-23 Cornell Research Foundation, Inc. Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen
WO2005016967A2 (en) * 2003-08-13 2005-02-24 Pfizer Products Inc. Modified human igf-1r antibodies
WO2009000098A2 (en) * 2007-06-25 2008-12-31 Esbatech Ag Sequence based engineering and optimization of single chain antibodies
GB0802931D0 (en) * 2008-02-18 2008-03-26 Queen Mary & Westfield College Synthetic scFv analogue to the 6313/G2 (anti angiotensin II type 1 receptor) monoclonal anitbody variable regions
US8243678B2 (en) * 2008-03-10 2012-08-14 Motorola Mobility, Inc. Hierarchical pilot structure in wireless communication systems
WO2009155723A2 (en) * 2008-06-25 2009-12-30 Esbatech, An Alcon Biomedical Research Unit Llc STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFα
KR101650165B1 (ko) * 2008-06-25 2016-08-22 에스바테크 - 어 노바티스 컴파니 엘엘씨 면역결합제의 용해도 최적화
AU2009264567B2 (en) * 2008-06-25 2014-06-12 Novartis Ag Humanization of rabbit antibodies using a universal antibody framework
US8796425B2 (en) * 2009-12-23 2014-08-05 Esbatech, An Alcon Biomedical Research Unit Llc Method for decreasing immunogenicity

Also Published As

Publication number Publication date
TWI633184B (zh) 2018-08-21
MX2012005345A (es) 2012-06-08
MX352871B (es) 2017-12-13
AU2010335950B2 (en) 2014-08-21
UY33154A (es) 2011-06-30
US8796425B2 (en) 2014-08-05
JP2013515460A (ja) 2013-05-09
JP2016094487A (ja) 2016-05-26
ZA201202299B (en) 2014-06-25
CL2012001696A1 (es) 2013-03-08
US20210214461A1 (en) 2021-07-15
ZA202006532B (en) 2022-04-28
JP6815083B2 (ja) 2021-01-20
EP4219545A1 (en) 2023-08-02
TW201925228A (zh) 2019-07-01
US20110152505A1 (en) 2011-06-23
RU2012130945A (ru) 2014-01-27
AR079700A1 (es) 2012-02-15
JP2015131855A (ja) 2015-07-23
CN109293768A (zh) 2019-02-01
WO2011075861A1 (en) 2011-06-30
RU2585534C2 (ru) 2016-05-27
UY39290A (es) 2021-07-30
TWI662128B (zh) 2019-06-11
KR20170084357A (ko) 2017-07-19
KR20120102061A (ko) 2012-09-17
ZA201402145B (en) 2018-05-30
CN102686608A (zh) 2012-09-19
CA2777527C (en) 2020-06-23
JP2017121254A (ja) 2017-07-13
TW201619383A (zh) 2016-06-01
US9803027B2 (en) 2017-10-31
JP5914353B2 (ja) 2016-05-11
US20150080555A1 (en) 2015-03-19
US10781268B2 (en) 2020-09-22
US20180016350A1 (en) 2018-01-18
CA2777527A1 (en) 2011-06-30
KR101721187B1 (ko) 2017-03-29
EP2516461A1 (en) 2012-10-31
JP2021153603A (ja) 2021-10-07
AU2010335950A1 (en) 2012-07-19
KR101758703B1 (ko) 2017-07-18
ZA201706443B (en) 2020-12-23
EP3498731A1 (en) 2019-06-19
KR20170036137A (ko) 2017-03-31
TW201125975A (en) 2011-08-01
JP2019141071A (ja) 2019-08-29

Similar Documents

Publication Publication Date Title
BR112012017051A2 (pt) método para diminuir a imunogenicidade
CY1122278T1 (el) Αντι il-36r αντισωματα
HRP20181932T1 (hr) Molekule protutijela koje imaju specifičnost za ljudski ox40
IL232420B (en) Antibody molecules with specificity for human ox40
MX356337B (es) Anticuerpos contra csf-1r humano y sus usos.
TW201129381A (en) Antibodies against human CSF-1R and uses thereof
BR112014009866A2 (pt) formulações de anticorpos e métodos
MX336682B (es) Anticuerpos contra csf-1r humanos y usos de los mismos.
ECSP12011581A (es) Inhibidores de bace
UA114611C2 (uk) Пестицидні композиції і способи, що їх стосуються
BR112013020259A2 (pt) tratamento de osteoartrite e dores
CR11776A (es) Inhibidores de bace
BR112012023015A2 (pt) imunoensaios para lenalidomida e talidomida
BR122018074319B8 (pt) Método para preparar um composto de fórmula 14
BR112013007237A2 (pt) ''método para produzir um anticorpo anti-ig-1r''
BR112013019520A2 (pt) método para produção de 2,3-butanodiol por fermentação
BR112012029985A2 (pt) métodos de determinação de rotatividade beta-amiloide no sangue.
BR112012025490A2 (pt) ''método para produção de 1,5 oebtanodiamina''
UA110332C2 (en) Use of 2,3-dihydroxypropyldodecanoate for treatment of seborrhea
EA201290243A1 (ru) Хиназолиновые соединения
WO2012063115A3 (en) Process for the preparation of rosuvastatin calcium via novel amine intermediate
BRPI1016111A2 (pt) "método de produzir aço"
GT200900215A (es) Nuevo procedimiento de obtencion de la forma cristalina v de la agomelatina.
WO2010109185A3 (en) Process for the preparation of doxazosin and salts thereof
BR112013007913A2 (pt) "método para operar uma instalação de combustão"

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements